The activity of an analogue of MPF (beta-endorphin 28-31) in a rat model of Parkinson's disease.
A single intrastriatal injection of a slow release formulation of a metabolically-stable MPF analogue was given to rats with lesioned right nigrostriatal pathways. After 6 weeks the turning behaviour of the rats in response to D-amphetamine began to decline, and after 12 weeks the reduction was marked and consistent. The implication of our results in the use of intracerebral grafts in parkinsonian patients is discussed.
Ensor
D M
DM
Department of Environmental and Evolutionary Biology, University of Liverpool, UK.
Morley
J S
JS
Redfern
R M
RM
Miles
J B
JB
D000595:Amino Acid Sequence; D000818:Animals; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D008297:Male; D008969:Molecular Sequence Data; D010300:Parkinson Disease / Q000188:drug therapy*; D010446:Peptide Fragments / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D001615:beta-Endorphin / Q000008:administration & dosage / Q000031:analogs & derivatives*
D003692:Delayed-Action Preparations; D010446:Peptide Fragments; C081845:beta-endorphin (28-31); D001615:beta-Endorphin